Showing 4691-4700 of 20465 results for "".
- Aesthetic Meet 2026: The Aesthetic Society Names Dr. Jamil Ahmad Presidenthttps://reachmd.com/news/aesthetic-meet-2026-the-aesthetic-society-names-dr-jamil-ahmad-president/2487120/The Aesthetic Society has named Jamil Ahmad, MD, as its President, and The Aesthetic Foundation has named David A. Sieber, MD, as President, during The Aesthetic MEET 2026 in Boston. Dr. Ahmad assumes leadership as The Society reports membership growth of more than 30%, with new members fr
- SCALE 2026: Dermatologists Navigate the Expanding Role of GLP-1 RAs in Skin Health and Aesthetic Carehttps://reachmd.com/news/scale-2026-dermatologists-navigate-the-expanding-role-of-glp-1s-in-skin-health-and-aesthetic-care/2487119/Dermatologists Navigate the Expanding Role of GLP-1 RAs in Skin Health and Aesthetic Care As use of GLP-1 receptor agonists (RAs) continues to surge, dermatologists are increasingly encountering the downstream effects of these medications in both medical and cosmetic pract
- AI Driven Triage in Pediatric Emergency Departmentshttps://reachmd.com/news/ai-driven-triage-in-pediatric-emergency-departments/2487096/Key Takeaways Pooled discrimination for admission, ICU admission, and mortality was strong and generally better than traditional triage scales. Performance varied in infants, children with complex chronic conditions, mental health presentations, and no
- ESCALON Trial Tests Corneal Endothelial Cell Therapy for Corneal Edemahttps://reachmd.com/news/escalon-trial-tests-corneal-endothelial-cell-therapy-for-corneal-edema/2487097/Key Takeaways Pooled month 12 data showed improvement in central corneal thickness and best-corrected visual acuity after treatment. No serious treatment-emergent adverse events were reported in study eyes, and common ocular events were included in the
- Cardiovascular Risk in Hidradenitis Suppurativahttps://reachmd.com/news/cardiovascular-risk-in-hidradenitis-suppurativa/2487105/Key Takeaways Pooled associations favored higher risks for ischemic or coronary heart disease, composite cardiovascular disease, myocardial infarction, heart failure, venous thromboembolism, and all-cause mortality. Hypertension was the most frequently
- Short-Acting Psychedelic Trial Reports Rapid MDD Symptom Reductionhttps://reachmd.com/news/short-acting-psychedelic-trial-reports-rapid-mdd-symptom-reduction/2487099/Key Takeaways Blinded treatment with intravenous DMT fumarate was associated with greater depressive symptom reduction at 2 weeks, with separation from placebo also reported at 1 week. Response and remission were reported at 1 week, 2 weeks, and explor
- Surgical Outcomes After Neoadjuvant Pembrolizumab in KEYNOTE-522https://reachmd.com/news/surgical-outcomes-after-neoadjuvant-pembrolizumab-in-keynote-522/2487109/Key Takeaways Pathological complete nodal response at surgery was higher with pembrolizumab plus chemotherapy than with placebo plus chemotherapy. Breast-conserving surgery, mastectomy, and the median intervals to surgery and to adjuvant therapy were s
- Scheduled Birth at Term Reduced Pre-Eclampsia in PREVENT-PEhttps://reachmd.com/news/scheduled-birth-at-term-reduced-pre-eclampsia-in-prevent-pe/2487110/Key Takeaways Birth with pre-eclampsia occurred in 3.9% of the intervention group and 5.6% of the usual-care group. The strategy used 36-week risk assessment and offered planned early-term birth when estimated pre-eclampsia risk was at least 1 in 50.</
- Prp Plus Hyaluronic Acid vs Crosslinked Hya in Knee Osteoarthritishttps://reachmd.com/news/prp-plus-hyaluronic-acid-vs-crosslinked-hya-in-knee-osteoarthritis/2487098/Key Takeaways At 6 months, WOMAC pain on walking favored PRP-HA, and investigators described PRP-HA as non-inferior on WOMAC pain responder assessment over 6 months. PASS WOMAC Pain responses favored PRP-HA, while OMERACT-OARSI and WOMAC pain MCII did
- Subcutaneous Guselkumab Meets Week 12 Endpoint In Ulcerative Colitishttps://reachmd.com/news/subcutaneous-guselkumab-meets-week-12-endpoint-in-ulcerative-colitis/2487100/Key Takeaways Subcutaneous guselkumab induction was associated with higher week 12 clinical remission than placebo. Week 24 clinical remission remained higher in both guselkumab groups than in the placebo group. Adverse events were reported at